Misplaced Pages

#229770

40-485: Compiled in English by editorial staff, the database provides a short abstract detailing the nature and use of the invention described in a patent and is indexed into alphanumeric technology categories to allow retrieval of relevant patent documents by users. Each record within the database defines a patent family , the grouping of patent documentation recorded at the various patent offices as protection of an invention

80-643: A United States federal court decision resulted in the release of approximately 1500 documents detailing how articles highlighting specific marketing messages written by unattributed writers, but "authored" by academics, are strategically placed in the medical literature – a practice known as ghostwriting . To release these documents, PLOS Medicine , represented by the public interest law firm Public Justice, and The New York Times , acted as "intervenors" in litigation against menopausal hormone manufacturers by women who developed breast cancer while taking hormones. PLOS Medicine argued that sealed documents identified during

120-536: A leading medical journal rejected this paper because of ethical concerns around how the trial was conducted before PLOS Medicine accepted it. The trial was stopped early by the Data and Safety Monitoring Board who advised the investigators to interrupt the trial and offer circumcision to the control group. The trial estimated that male circumcision protected 60% (95% CI: 32%–76%) for female-to-male HIV transmission. The results of this trial along with two others led to

160-490: A particular subject and is often used to help the reader quickly ascertain the paper's purpose. When used, an abstract always appears at the beginning of a manuscript or typescript, acting as the point-of-entry for any given academic paper or patent application . Abstracting and indexing services for various academic disciplines are aimed at compiling a body of literature for that particular subject. The terms précis or synopsis are used in some publications to refer to

200-505: A recent study statistically comparing publications with or without graphical abstracts with regard to several output parameters reflecting visibility failed to demonstrate an effectiveness of graphical abstracts for attracting attention to scientific publications. Various methods can be used to evaluate abstract quality, e.g. rating by readers, checklists), and readability measures (such as Flesch Reading Ease ). PLOS Medicine PLOS Medicine (formerly styled PLoS Medicine )

240-533: A short comment and a longer analysis. Ioannidis has answered this critique. A profile of Ioannidis' work including a discussion of his 2005 paper appeared in the November 2010 issue of The Atlantic . The first randomized controlled trial to assess the effect of male circumcision on female to male HIV transmission was published in 2005 by Bertran Auvert and colleagues in PLOS Medicine . The Lancet

280-602: Is a peer-reviewed weekly medical journal covering the full spectrum of the medical sciences . It began operation on October 19, 2004, as the second journal of the Public Library of Science (PLOS), a non-profit open access publisher . All content in PLOS Medicine is published under the Creative Commons "by-attribution" license . To fund the journal, the publication's business model requires in most cases that authors pay publication fees . The journal

320-410: Is a significant selling point for the reprint or electronic form of the full text. The abstract can convey the main results and conclusions of a scientific article but the full text article must be consulted for details of the methodology, the full experimental results, and a critical discussion of the interpretations and conclusions. Abstracts are occasionally inconsistent with full reports. This has

360-522: Is generally agreed that one must not base reference citations on the abstract alone, but the content of an entire paper. This is because abstracts may not be fully representative of the full report or article. Therefore, basing reference citations solely on the information present in the abstract could be misleading. According to the results of a study published in PLOS Medicine , the "exaggerated and inappropriate coverage of research findings in

400-406: Is often expected to tell a complete story of the paper, as for most readers, abstract is the only part of the paper that will be read. It should allow the reader to give an elevator pitch of the full paper. An academic abstract typically outlines four elements relevant to the completed work: It may also contain brief references, although some publications' standard style omits references from

440-482: Is sought around the world. Each patent family is grouped around a Basic Patent, which is usually the first published example of the invention. All subsequent filings are referred back to the Basic Patent, and are referred to as Equivalent Patents. On this basis, the database has some 20 million "inventions", corresponding to tens of millions of patents, with almost a million new inventions added each year. From 2008,

SECTION 10

#1732772608230

480-725: The Tebtunis papyri found in the Ancient Egyptian town of Tebtunis contain abstracts of legal documents. During the Middle Ages , the pages of scholarly texts contained summaries of their contents as marginalia , as did some manuscripts of the Code of Justinian . The use of abstracts to summarise science originates in the early 1800s, when the secretary of the Royal Society would record brief summaries of talks into

520-715: The World Health Organization (WHO) assessing the evidence for male circumcision to prevent HIV transmission. The WHO and UNAIDS subsequently issued recommendations concerning male circumcision and HIV/AIDS including suggestions for government strategic plans, advocacy challenges and exploring the role of new technologies for voluntary medical male circumcision (VMMC) such as Prepex and other medical devices. Several Ministries of Health along with key stakeholders have committed to scaling up VMMC for HIV prevention in Southern and Eastern Africa. In July 2009,

560-492: The complete abstract , is a compendious summary of a paper's substance and its background, purpose, methodology, results, and conclusion. Usually between 100 and 200 words, the informative abstract summarizes the paper's structure, its major topics and key points. A format for scientific short reports that is similar to an informative abstract has been proposed in recent years. Informative abstracts may be viewed as standalone documents. The descriptive abstract , also known as

600-503: The limited abstract or the indicative abstract , provides a description of what the paper covers without delving into its substance. A descriptive abstract is akin to a table of contents in paragraph form. During the late 2000s, due to the influence of computer storage and retrieval systems such as the Internet , some scientific publications, primarily those published by Elsevier , started including graphical abstracts alongside

640-408: The minutes of each meeting, which were referred to as 'abstracts'. The Royal Society abstracts from 1800 – 1837 were later collated and published in the society's journal Philosophical Transactions , with the first group appearing in 1832. These abstracts were generally one or more pages long. Other learned societies adopted similar practices. The Royal Astronomical Society (RAS) may have been

680-534: The abstract as an abstract and not about the work it summarizes: for instance, if you are writing about different styles of writing abstracts used in the sciences and humanities." The history of abstracting dates back to the point when it was felt necessary to summarise the content of documents in order to make the information contained in them more accessible. In Mesopotamia during the early second millennium BCE, clay envelopes designed to protect enclosed cuneiform documents from tampering were inscribed either with

720-488: The abstract, reserving them for the article body (which, by definition, treats the same topics but in more depth). Abstract length varies by discipline and publisher requirements. Typical length ranges from 100 to 500 words, but very rarely more than a page and occasionally just a few words. An abstract may or may not have the section title of "abstract" explicitly listed as an antecedent to content. Sometimes, abstracts are sectioned logically as an overview of what appears in

760-487: The accuracy of information reported in a journal abstract with that reported in the text of the full publication have found claims that are inconsistent with, or missing from, the body of the full article." According to the Modern Language Association , there are almost no circumstances in which it is acceptable to cite an abstract: "It only makes sense to cite an abstract if you are writing about

800-438: The authors to easily explain their papers. Many scientific publishers currently encourage authors to supplement their articles with graphical abstracts, in the hope that such a convenient visual summary will facilitate readers with a clearer outline of papers that are of interest and will result in improved overall visibility of the respective publication. However, the validity of this assumption has not been thoroughly studied, and

840-402: The basis for selecting research that is proposed for presentation in the form of a poster, platform/oral presentation or workshop presentation at an academic conference . Most bibliographic databases only index abstracts rather than providing the entire text of the paper. Full texts of scientific papers must often be purchased because of copyright and/or publisher fees and therefore the abstract

SECTION 20

#1732772608230

880-482: The category "Medicine, General & Internal". In 2005 PLOS Medicine published an essay by John P. A. Ioannidis entitled " Why Most Published Research Findings Are False ". The essay used a simulation approach to demonstrate that for most study designs and settings it is more likely for a research claim to be false than true due to inherent biases in the way that modern science is conducted. This paper has met much approval, though Goodman and Greenland criticized it in

920-554: The discovery process for the court case, which demonstrated the practice of ghostwriting, should be made available to the public. The documents were initially made publicly available on the PLOS Medicine website but they are now available as part of the Drug Industry Documents Archive at the University of California, San Francisco . In 2010 PLOS Medicine published the first academic analysis of

960-435: The documents by Adriane Fugh-Berman. Her article revealed that the pharmaceutical company Wyeth used ghostwritten articles to mitigate the perceived risks of breast cancer associated with menopausal hormone therapy (HT), to defend the unsupported cardiovascular "benefits" of HT, and to promote off-label, unproven uses of HT such as the prevention of dementia , Parkinson's disease , vision problems, and wrinkles. The article

1000-577: The first to publish its abstracts: the Monthly Notices of the RAS launched in 1827, containing (among other things) abstracts of talks given at their monthly meetings; the full papers were published months or years later in the Memoirs of the RAS . The RAS abstracts were between one and three paragraphs long. In both cases, these early abstracts were written by the learned society, not the author of

1040-516: The full text of the document or a summary. In the Greco-Roman world , many texts were abstracted: summaries of non-fiction works were known as epitomes , and in many cases the only information about works which have not survived to modernity comes from their epitomes which have survived. Similarly, the text of many ancient Greek and Roman plays commenced with a hypothesis which summed up the play's plot. Non-literary documents were also abstracted:

1080-497: The greatest toll on health globally. In 2009 the journal reaffirmed its scope and noted that it would use an evidence-based approach to give highest priority to studies on diseases and risk factors that cause the greatest burden worldwide. From the outset the journal noted that it would not be part of "the cycle of dependency that has formed between journals and the pharmaceutical industry". The journal does not publish advertisements for pharmaceutical products or medical devices and

1120-632: The journal's open-access license means that it cannot benefit from exclusive reprint sales. The journal is abstracted and indexed in Index Medicus / MEDLINE / PubMed , the Science Citation Index Expanded , Current Contents /Clinical Medicine, and BIOSIS Previews . According to the Journal Citation Reports , the journal had a 2014 impact factor of 14.429, ranking it 7th out of 153 journals in

1160-639: The need for access to all clinical trial data held by pharmaceutical companies and regulators, and detailed reasons given by Roche for not sharing data on Tamiflu. In a commissioned perspective article published in the same issue of PLOS Medicine , regulators from the European Medicines Agency (EMA) and other national regulatory bodies outlined a shift in their stance on access to clinical trial data but also highlighted challenges that would need to be overcome. The regulators noted, "[w]e consider it neither desirable nor realistic to maintain

1200-502: The news media" is ultimately related to inaccurately reporting or over-interpreting research results in many abstract conclusions. A study published in JAMA concluded that "inconsistencies in data between abstract and body and reporting of data and other information solely in the abstract are relatively common and that a simple educational intervention directed to the author is ineffective in reducing that frequency." Other "studies comparing

1240-927: The number format of the Basic Patent Identifier (the Accession Number ) changed, to allow up to 3.6 million records per year to be added, as the previous format only allowed a maximum of 1 million new records a year. This is due to the steady increase in unique patents filed each year. The database is produced by information provider Clarivate Analytics , previously part of Thomson Reuters . Derwent produces its own proprietary patent classification codes, called manual codes. The classification system contains subdivisions related to chemical, electrical and mechanical engineering subject matter. Derwent indexers add standardized 4-letter codes to DWPI records to represent certain patent-holding companies. These codes are not available for all companies - only

Derwent World Patents Index - Misplaced Pages Continue

1280-467: The paper, with any of the following subheadings: Background, Introduction , Objectives , Methods , Results, Discussion, Conclusions. Abstracts in which these subheadings are explicitly given are often called structured abstracts . Abstracts that comprise one paragraph (no explicit subheadings) are often called unstructured abstracts . Abstracts are important enough that IMRAD is even sometimes recast as AIMRAD . The informative abstract , also known as

1320-686: The paper. Perhaps the earliest example of an abstract published alongside the paper it summarises was the 1919 paper On the Irregularities of Motion of the Foucault Pendulum published in the Physical Review of the American Physical Society , which often published abstracts thereafter. Abstracts are protected under copyright law just as any other form of written speech is protected. Abstract

1360-411: The potential to mislead clinicians who rely solely on the information present in the abstract without consulting the full report. An abstract allows one to sift through copious numbers of papers for ones in which the researcher can have more confidence that they will be relevant to their research. Once papers are chosen based on the abstract, they must be read carefully to be evaluated for relevance. It

1400-418: The same thing that other publications might call an "abstract". In management reports, an executive summary usually contains more information (and often more sensitive information) than the abstract does. Academic literature uses the abstract to succinctly communicate complex research. An abstract may act as a stand-alone entity instead of a full paper. As such, an abstract is used by many organizations as

1440-495: The status quo of limited availability of regulatory trials data" and concluded, "[w]e welcome debate on these issues, and remain confident that satisfactory solutions can be found to make complete trial data available in a way that will be in the best interest of public health". The article marked a move towards the proactive disclosure of clinical trial data and led to the EMA holding a workshop to establish how this could be done. At

1480-467: The text abstracts. The graphic is intended to summarize or be an exemplar for the main thrust of the article. It is not intended to be as exhaustive a summary as the text abstract, rather it is supposed to indicate the type, scope, and technical coverage of the article at a glance. The use of graphical abstracts has been generally well received by the scientific community . Moreover, some journals also include video abstracts and animated abstracts made by

1520-436: The top patent holding companies have these standard Derwent codes. Derwent World Patents Index can trace its origin to Delphion patent database, that originated in pre- World Wide Web era. Thomson Reuters acquired Delphion first, and them sold it to Clarivate in 2016. Abstract (summary) An abstract is a brief summary of a research article, thesis , review, conference proceeding , or any in-depth analysis of

1560-436: Was published online and in a printed format until 2005 and is now only published online. The journal's acting chief editor is Clare Stone, who replaced the previous chief editor, Larry Peiperl, in 2018. The journal's initial aim was to provide an open-access alternative to existing top-tier journals such as The New England Journal of Medicine and The Lancet and has concentrated on publishing papers on diseases that take

1600-433: Was subsequently covered by The Guardian . In April 2012 PLOS Medicine published an article by three researchers who were involved in ongoing updates of a Cochrane Collaboration review of neuraminidase inhibitors for treating influenza , describing their experience of trying to gain access to clinical study reports for the antiviral Tamiflu ( oseltamivir ) from the drug's manufacturer Roche . The article outlined

#229770